Active Clinical Trials at OOS

All Clinical Trials

Amplitude (67652000PCR3002)

Tumor site:
Prostate
Description:
A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants with Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
Available at:
Notes:
Sponsor: Janssen; NCT Number: NCT04497844

ASTX030-01

Tumor site:
Hematologic (MDS, CMML, AML)
Description:
A Multi-phase, Dose-Escalation followed by an Open-label, Randomized, Crossover Study of Oral ASTX030 (Cedazuridine and Azacitidine Given in Combination) Versus Subcutaneous Azacitidine in Subjects with Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
Available at:
Notes:
Sponsor: Astex; NCT Number: NCT04256317

BDX-00146

Tumor site:
Lung
Description:
An Observational Study Assessing the Clinical Effectiveness of the VeriStrat® Test and Validating Immunotherapy Tests in Subjects with Non-Small Cell Lung Cancer (INSIGHT)
Available at:
Notes:
Sponsor: Biodesix Inc; NCT Number: NCT03289780

Bespoke 20-041-NCP

Tumor site:
Colorectal
Description:
An Observational Study of ctDNA Guided Therapy in Colorectal Cancer.
Available at:
Notes:
Sponsor: Natera Inc; NCT Number: NCT04264702

EQ132-201

Tumor site:
Breast
Description:
A Phase 2 Study to Evaluate the Safety and Efficacy of Lerociclib in Participants with Advanced Breast Cancer
Available at:
Notes:
Sponsor: EQRx, Inc; NCT Number: NCT05085002

LOXO-BTK-20019

Tumor site:
Mantle Cell Lymphoma
Description:
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Available at:
Notes:
Sponsor: Loxo Oncology, Inc; NCT Number: NCT04662255

Mirati KRYSTAL 7

Tumor site:
Lung (NSCLC)
Description:
Phase 2 Trial of MRTX849 Plus Pembrolizumab for NSCLC With KRAS G12C Mutation (KRYSTAL-7)
Available at:
Notes:
Sponsor: Mirati Therapeutics Inc; NCT Numer: NCT04613596

Mirati KRYSTAL 12

Tumor site:
Lung (NSCLC)
Description:
Phase 3 Study of MRTX849 vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)
Available at:
Notes:
Sponsor: Mirati Therapeutics Inc; NCT Number: NCT04685135

PARADIGM

Tumor site:
NSCLC, Melanoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
Description:
PARADIGM: Pursuit to Analyze and Reveal Associated Drivers of Immunotherapy outcomes through the Gut Microbiome
Available at:
Notes:
Sponsor: VastBiome; NCT Number: NCT05037825
Page 1 of
Page: